Evidence map›Paper›PMID 42614839›Full record

ArticleACS pharmacology & translational science2026

Discovery of Cyclic Peptides Targeting the BRAF Dimer Interface as Dual Inhibitors.

Kai Zhang, Wen-Wen Zhang, Peng Dong, Guangyao Wang, Conghao Gai, Xiaoyun Chai, Xiaobin Zhuo, Yuxin Xiao, Kaixuan Hu, Jing Li and 3 more

Abstract read
In one paragraph

Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kai ZhangSchool of Pharmacy, Naval Medical University (Second Military Medical University), Shanghai 200433, PR China.
Wen-Wen ZhangSchool of Pharmacy, Naval Medical University (Second Military Medical University), Shanghai 200433, PR China.ORCID https://orcid.org/0009-0007-8571-8044
Peng DongSchool of Pharmacy, Naval Medical University (Second Military Medical University), Shanghai 200433, PR China.ORCID https://orcid.org/0009-0009-0166-8110
Guangyao WangSchool of Pharmacy, Naval Medical University (Second Military Medical University), Shanghai 200433, PR China.
Conghao GaiSchool of Pharmacy, Naval Medical University (Second Military Medical University), Shanghai 200433, PR China.ORCID https://orcid.org/0000-0001-6760-5045
Xiaoyun ChaiSchool of Pharmacy, Naval Medical University (Second Military Medical University), Shanghai 200433, PR China.ORCID https://orcid.org/0000-0001-9688-9091
Xiaobin ZhuoSchool of Pharmacy, Naval Medical University (Second Military Medical University), Shanghai 200433, PR China.
Yuxin XiaoKey Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, School of Pharmacy, Chengdu University, Chengdu 610106, PR China.
Kaixuan HuKey Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, School of Pharmacy, Chengdu University, Chengdu 610106, PR China.
Jing LiKey Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, School of Pharmacy, Chengdu University, Chengdu 610106, PR China.
Pei-Chao ZhangSchool of Pharmacy, Naval Medical University (Second Military Medical University), Shanghai 200433, PR China.
Qingjie ZhaoSchool of Pharmacy, Naval Medical University (Second Military Medical University), Shanghai 200433, PR China.
Yan ZouSchool of Pharmacy, Naval Medical University (Second Military Medical University), Shanghai 200433, PR China.ORCID https://orcid.org/0000-0002-5266-7275

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RAF dimerization is crucial for oncogenic signaling in RAS mutant tumors, contributing to resistance to mitogen-activated protein kinase pathway inhibitors by promoting dysregulated BRAF dimerization. This makes it a promising target for overcoming resistance caused by paradoxical extracellular signal-regulated kinase (ERK) signaling activation resulting from BRAF mutations (e.g., BRAF

Indexed as

anti-invasionantitumorBRAF dimerpeptide inhibitorsPPIs

Identifiers

PMID42614839
PMCPMC13482880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.